<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34097573</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1369-1635</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>33</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Platelets</Title>
          <ISOAbbreviation>Platelets</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.</ArticleTitle>
        <Pagination>
          <StartPage>404</StartPage>
          <EndPage>415</EndPage>
          <MedlinePgn>404-415</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/09537104.2021.1934665</ELocationID>
        <Abstract>
          <AbstractText>Several Janus kinase (JAK) inhibitors (jakinibs) have recently been approved to treat inflammatory, autoimmune and hematological conditions. Despite emerging roles for JAKs and downstream signal transducer and activator of transcription (STAT) proteins in platelets, it remains unknown whether jakinibs affect platelet function. Here, we profile platelet biochemical and physiological responses <i>in vitro</i> in the presence of five different clinically relevant jakinibs, including ruxolitinib, upadacitinib, oclacitinib, baricitinib and tofacitinib. Flow cytometry, microscopy and other assays found that potent JAK1/2 inhibitors baricitinib and ruxolitinib reduced platelet adhesion to collagen, as well as platelet aggregation, secretion and integrin α<sub>IIb</sub>β<sub>3</sub> activation in response to the glycoprotein VI (GPVI) agonist collagen-related peptide (CRP-XL). Western blot analysis demonstrated that jakinibs reduced Akt phosphorylation and activation following GPVI activation, where ruxolitinib and baricitinib prevented DAPP1 phosphorylation. In contrast, jakinibs had no effects on platelet responses to thrombin. Inhibitors of GPVI and JAK signaling also abrogated platelet STAT5 phosphorylation following CRP-XL stimulation. Additional pharmacologic experiments supported roles for STAT5 in platelet secretion, integrin activation and cytoskeletal responses. Together, our results demonstrate that ruxolitinib and baricitinib have inhibitory effects on platelet function <i>in vitro</i> and support roles for JAK/STAT5 pathways in GPVI/ITAM mediated platelet function.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Parra-Izquierdo</LastName>
            <ForeName>Iván</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Knight Cardiovascular Institute and Division of Cardiology, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Melrose</LastName>
            <ForeName>Alexander R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Knight Cardiovascular Institute and Division of Cardiology, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pang</LastName>
            <ForeName>Jiaqing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lakshmanan</LastName>
            <ForeName>Hari Hara Sudhan</ForeName>
            <Initials>HHS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reitsma</LastName>
            <ForeName>Stéphanie E</ForeName>
            <Initials>SE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vavilapalli</LastName>
            <ForeName>Sai Hitesh</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>Knight Cardiovascular Institute and Division of Cardiology, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Larson</LastName>
            <ForeName>Mark K</ForeName>
            <Initials>MK</Initials>
            <AffiliationInfo>
              <Affiliation>Biology Department, Augustana University, Sioux Falls, SD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shatzel</LastName>
            <ForeName>Joseph J</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Medical Oncology, School of Medicine, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McCarty</LastName>
            <ForeName>Owen J T</ForeName>
            <Initials>OJT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Medical Oncology, School of Medicine, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aslan</LastName>
            <ForeName>Joseph E</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
              <Affiliation>Knight Cardiovascular Institute and Division of Cardiology, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Chemical Physiology and Biochemistry, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 HL101972</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL146549</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL151367</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Platelets</MedlineTA>
        <NlmUniqueID>9208117</NlmUniqueID>
        <ISSNLinking>0953-7104</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001384">Azetidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000075242">Janus Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010980">Platelet Membrane Glycoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011687">Purines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82S8X8XX8H</RegistryNumber>
          <NameOfSubstance UI="C540383">ruxolitinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>ISP4442I3Y</RegistryNumber>
          <NameOfSubstance UI="C000596027">baricitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001384" MajorTopicYN="N">Azetidines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000075242" MajorTopicYN="N">Janus Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015539" MajorTopicYN="N">Platelet Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010973" MajorTopicYN="N">Platelet Adhesiveness</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010980" MajorTopicYN="N">Platelet Membrane Glycoproteins</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Baricitinib</Keyword>
        <Keyword MajorTopicYN="N">GPVI</Keyword>
        <Keyword MajorTopicYN="N">JAK</Keyword>
        <Keyword MajorTopicYN="N">STAT5</Keyword>
        <Keyword MajorTopicYN="N">platelets</Keyword>
        <Keyword MajorTopicYN="N">ruxolitinib</Keyword>
      </KeywordList>
      <CoiStatement>CONFLICT OF INTEREST. The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>7</Day>
          <Hour>17</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34097573</ArticleId>
        <ArticleId IdType="mid">NIHMS1714252</ArticleId>
        <ArticleId IdType="pmc">PMC8648864</ArticleId>
        <ArticleId IdType="doi">10.1080/09537104.2021.1934665</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Subramaniam PS, Torres BA &amp; Johnson HM
So many ligands, so few transcription factors: a new paradigm for signaling through the STAT transcription factors. Cytokine
15, 175–187 (2001).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11563878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiu H. &amp; Nicholson SE
Biology and significance of the JAK/STAT signalling pathways. Growth Factors Chur Switz. 30, 88–106 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3762697</ArticleId>
            <ArticleId IdType="pubmed">22339650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aaronson DS &amp; Horvath CM
A road map for those who don’t know JAK-STAT. Science
296, 1653–1655 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12040185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kontzias A, Kotlyar A, Laurence A, Changelian P. &amp; O’Shea JJ
Jakinibs: A New Class of Kinase Inhibitors in Cancer and Autoimmune Disease. Curr. Opin. Pharmacol
12, 464–470 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3419278</ArticleId>
            <ArticleId IdType="pubmed">22819198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKeage K. Ruxolitinib: A Review in Polycythaemia Vera. Drugs
75, 1773–1781 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26362333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plosker GL
Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs
75, 297–308 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25601187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka Y. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. J. Biochem. (Tokyo)
158, 173–179 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26152731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Genovese MC
et al.
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. The Lancet
391, 2513–2524 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29908670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markham A. Baricitinib: First Global Approval. Drugs
77, 697–704 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28290136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzales AJ
et al.
Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J. Vet. Pharmacol. Ther
37, 317–324 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4265276</ArticleId>
            <ArticleId IdType="pubmed">24495176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Virtanen, A. T, Haikarainen T, Raivola J. &amp; Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs
33, 15–32 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6373396</ArticleId>
            <ArticleId IdType="pubmed">30701418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajasimhan S, Pamuk O. &amp; Katz JD
Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk. Drugs Aging
37, 551–558 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7387323</ArticleId>
            <ArticleId IdType="pubmed">32514874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verden A, Dimbil M, Kyle R, Overstreet B. &amp; Hoffman KB
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors. Drug Saf. 41, 357–361 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29196988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehta P, Ciurtin C, Scully M, Levi M. &amp; Chambers RC
JAK inhibitors in COVID-19: need for vigilance regarding increased inherent thrombotic risk. Eur. Respir. J (2020) doi:10.1183/13993003.01919-2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.01919-2020</ArticleId>
            <ArticleId IdType="pmc">PMC7338400</ArticleId>
            <ArticleId IdType="pubmed">32631841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barraco F. et al.
Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis. Br. J. Haematol (2020) doi:10.1111/bjh.16729.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.16729</ArticleId>
            <ArticleId IdType="pubmed">32583458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aslan JE
Platelet Shape Change. in Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics: an Update (eds. Gresele P, Kleiman NS, Lopez JA &amp; Page CP) 321–336 (Springer International Publishing, 2017). doi:10.1007/978-3-319-47462-5_24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-319-47462-5_24</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koupenova M, Clancy L, Corkrey HA &amp; Freedman JE
Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis. Circ. Res
122, 337–351 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5777300</ArticleId>
            <ArticleId IdType="pubmed">29348254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aslan JE
Platelet Proteomes, Pathways, and Phenotypes as Informants of Vascular Wellness and Disease. Arterioscler. Thromb. Vasc. Biol
41, 999–1011 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7980774</ArticleId>
            <ArticleId IdType="pubmed">33441027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Research C. for D. E. and. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). FDA (2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Taylor PC
et al.
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis Rheumatol. Hoboken NJ
71, 1042–1055 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6618316</ArticleId>
            <ArticleId IdType="pubmed">30663869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samuelson BT
et al.
The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul. Fibrinolysis Int. J. Haemost. Thromb
27, 648–652 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26569516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marchetti M. et al.
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. Leukemia
31, 882–888 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27740634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison CN
et al.
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 5, e73–e81 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29275119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verstovsek S. et al.
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med
366, 799–807 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4822164</ArticleId>
            <ArticleId IdType="pubmed">22375971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shatzel JJ
et al.
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J. Thromb. Haemost. JTH
15, 835–847 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6152914</ArticleId>
            <ArticleId IdType="pubmed">28182323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng TJ
et al.
Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function. Am. J. Physiol. Cell Physiol (2021) doi:10.1152/ajpcell.00296.2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpcell.00296.2020</ArticleId>
            <ArticleId IdType="pmc">PMC8163578</ArticleId>
            <ArticleId IdType="pubmed">33689480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rigg RA
et al.
Oral administration of Bruton’s Tyrosine Kinase (Btk) inhibitors impairs GPVI-mediated platelet function. Am. J. Physiol.-Cell Physiol (2015) doi:10.1152/ajpcell.00325.2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpcell.00325.2015</ArticleId>
            <ArticleId IdType="pmc">PMC4971826</ArticleId>
            <ArticleId IdType="pubmed">26659727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loren CP
et al.
The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thromb. Res
135, 155–160 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4272760</ArticleId>
            <ArticleId IdType="pubmed">25527332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu W-J
et al.
Role of a Janus kinase 2-dependent signaling pathway in platelet activation. Thromb. Res
133, 1088–1096 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24731555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H. et al.
Piperlongumine Blocks JAK2-STAT3 to Inhibit Collagen-Induced Platelet Reactivity Independent of Reactive Oxygen Species†. PLOS ONE
10, e0143964 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4672935</ArticleId>
            <ArticleId IdType="pubmed">26645674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Z. et al.
A novel STAT3 inhibitor negatively modulates platelet activation and aggregation. Acta Pharmacol. Sin
38, 651–659 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5457693</ArticleId>
            <ArticleId IdType="pubmed">28260800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Z. et al.
STAT3 Regulates Collagen-Induced Platelet Aggregation Independent of its Transcription Factor Activity. Circulation
127, 476–485 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4472638</ArticleId>
            <ArticleId IdType="pubmed">23266857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heinrich PC, Behrmann I, Müller-Newen G, Schaper F. &amp; Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J
334 ( Pt 2), 297–314 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1219691</ArticleId>
            <ArticleId IdType="pubmed">9716487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houck KL
et al.
Physical proximity and functional cooperation of glycoprotein 130 and glycoprotein VI in platelet membrane lipid rafts. J. Thromb. Haemost
17, 1500–1510 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31145836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eaton N. et al.
Bleeding diathesis in mice lacking JAK2 in platelets. Blood Adv. (In press).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8361459</ArticleId>
            <ArticleId IdType="pubmed">34342643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Izquierdo I. et al.
A Comprehensive Tyrosine Phosphoproteomic Analysis Reveals Novel Components of the Platelet CLEC-2 Signaling Cascade. Thromb. Haemost
120, 262–276 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31901221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babur Ö
et al.
Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs. Blood
136, 2346–2358 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7702475</ArticleId>
            <ArticleId IdType="pubmed">32640021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodríguez-Liñares B. &amp; Watson SP
Phosphorylation of JAK2 in thrombin-stimulated human platelets. FEBS Lett. 352, 335–338 (1994).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7925997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tibbles HE
et al.
Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation. J. Biol. Chem
276, 17815–17822 (2001).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11278899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ezumi Y, Takayama H. &amp; Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett. 374, 48–52 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7589510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyakawa Y. et al.
Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood
87, 439–446 (1996).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8555464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore SF, Smith NR, Blair TA, Durrant TN &amp; Hers I. Critical roles for the phosphatidylinositide 3-kinase isoforms p110β and p110γ in thrombopoietin-mediated priming of platelet function. Sci. Rep
9, 1468 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6365529</ArticleId>
            <ArticleId IdType="pubmed">30728366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hobbs CM
et al.
JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood
122, 3787–3797 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3843237</ArticleId>
            <ArticleId IdType="pubmed">24085768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shinobu Matsuura
et al.
Platelet Dysfunction and Thrombosis in JAK2V617F-Mutated Primary Myelofibrotic Mice. Arterioscler. Thromb. Vasc. Biol
40, e262–e272 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7605151</ArticleId>
            <ArticleId IdType="pubmed">32814440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dellas C. et al.
Leptin signalling and leptin-mediated activation of human platelets: importance of JAK2 and the phospholipases Cgamma2 and A2. Thromb. Haemost
98, 1063–1071 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18000612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bye AP, Unsworth AJ &amp; Gibbins JM
Platelet signaling: a complex interplay between inhibitory and activatory networks. J. Thromb. Haemost
14, 918–930 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4879507</ArticleId>
            <ArticleId IdType="pubmed">26929147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stalker TJ, Newman DK, Ma P, Wannemacher KM &amp; Brass LF
Platelet signaling. Handb. Exp. Pharmacol
59–85 (2012) doi:10.1007/978-3-642-29423-5_3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-642-29423-5_3</ArticleId>
            <ArticleId IdType="pmc">PMC4785017</ArticleId>
            <ArticleId IdType="pubmed">22918727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kehrel B. et al.
Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood
91, 491–499 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9427702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tt Z. et al.
Phosphoinositide 3-kinase-regulated adapters in lymphocyte activation. Immunol. Rev
232, 255–272 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19909369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiwanuka KN
et al.
Stat5B is required for IgE-Mediated mast cell function in vitro and in vivo. Cell. Immunol
364, 104344 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8104437</ArticleId>
            <ArticleId IdType="pubmed">33780747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durrant TN
et al.
In-depth PtdIns(3,4,5)P3 signalosome analysis identifies DAPP1 as a negative regulator of GPVI-driven platelet function. Blood Adv. 1, 918–932 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5726495</ArticleId>
            <ArticleId IdType="pubmed">29242851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Z. et al.
STAT3 Regulates Collagen-Induced Platelet Aggregation Independent of Its Transcription Factor Activity. Blood
116, 157–157 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller J, Sperl B, Reindl W, Kiessling A. &amp; Berg T. Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem Eur. J. Chem. Biol
9, 723–727 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18247434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Margraf A. &amp; Zarbock A. Platelets in Inflammation and Resolution. J. Immunol
203, 2357–2367 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31636134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gear ARL &amp; Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirc. N. Y. N 1994
10, 335–350 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12851650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’ Atri LP &amp; Schattner M. Platelet toll-like receptors in thromboinflammation. Front. Biosci. Landmark Ed
22, 1867–1883 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28410150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fragoulis GE, McInnes IB &amp; Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology
58, i43–i54 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6390879</ArticleId>
            <ArticleId IdType="pubmed">30806709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banerjee S, Biehl A, Gadina M, Hasni S. &amp; Schwartz DM
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs
77, 521–546 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7102286</ArticleId>
            <ArticleId IdType="pubmed">28255960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haines E. et al.
Tyrosine phosphorylation of Grb2: role in prolactin/epidermal growth factor cross talk in mammary epithelial cell growth and differentiation. Mol. Cell. Biol
29, 2505–2520 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2682022</ArticleId>
            <ArticleId IdType="pubmed">19273609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abell K. &amp; Watson CJ
The Jak/Stat pathway: a novel way to regulate PI3K activity. Cell Cycle Georget. Tex
4, 897–900 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15970662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Y. et al.
JAK/STAT and PI3K/AKT pathways form a mutual transactivation loop and afford resistance to oxidative stress-induced apoptosis in cardiomyocytes. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol
21, 305–314 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18441519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxena NK
et al.
Concomitant Activation of the JAK/STAT, PI3K/AKT, and ERK Signaling Is Involved in Leptin-Mediated Promotion of Invasion and Migration of Hepatocellular Carcinoma Cells. Cancer Res. 67, 2497–2507 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2925446</ArticleId>
            <ArticleId IdType="pubmed">17363567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richardson P. et al.
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet
395, e30–e31 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7137985</ArticleId>
            <ArticleId IdType="pubmed">32032529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parra-Izquierdo I. &amp; Aslan JE
Perspectives on Platelet Heterogeneity and Host Immune Response in Coronavirus Disease 2019 (COVID-19). Semin. Thromb. Hemost
46, 826–830 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7645832</ArticleId>
            <ArticleId IdType="pubmed">32882716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blair TA
et al.
Phosphoinositide 3-kinase p110α negatively regulates thrombopoietin-mediated platelet activation and thrombus formation. Cell. Signal
50, 111–120 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29793021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grimley PM, Dong F. &amp; Rui H. Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev. 10, 131–157 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10743504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kollmann S. et al.
Twins with different personalities: STAT5B—but not STAT5A—has a key role in BCR/ABL-induced leukemia. Leukemia
33, 1583–1597 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6755975</ArticleId>
            <ArticleId IdType="pubmed">30679796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drayer AL, Boer A-K, Los EL, Esselink MT &amp; Vellenga E. Stem cell factor synergistically enhances thrombopoietin-induced STAT5 signaling in megakaryocyte progenitors through JAK2 and Src kinase. Stem Cells Dayt. Ohio
23, 240–251 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15671147</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
